Jennifer R. Diamond

University of Colorado Anschutz Medical Campus

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 17 papers. Top paper: “Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial”.

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial

Annals of Oncology(2020)10.1016/j.annonc.2020.09.004

N/A

5.0DataRank · unranked

145 citations

Jennifer R. Diamond, Linda T. Vahdat, Sara M. Tolaney, Dejan Juric, Joyce O’Shaughnessy +11 more

Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0117

N/A

0.603DataRank · unranked

12 citations

William J. Gradishar, Ursa Brown-Glaberman, Pavani Chalasani, Andrew Brenner, Alison Stopeck +8 more

Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer

Cancers(2020)10.3390/cancers12030719

N/A

0.483DataRank · unranked

24 citations

Dennis M. Simmons, Stacey M. Bagby, Sarah J. Hartman, Betelehem W. Yacob, Brian Gittleman +7 more

Paraneoplastic Encephalitis Associated with Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Journal of Breast Cancer(2020)10.4048/jbc.2021.24.e2

N/A

0DataRank · unranked

2 citations

Jennifer R. Diamond, Jodi Kagihara, Sharon B. Sams, Rebecca C. Shay

Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes

Frontiers in Immunology(2021)10.3389/fimmu.2021.607282

N/A

0DataRank · unranked

50 citations

Anna Capasso, Matthew S. Lewis, Stacey M. Bagby, Sarah J. Hartman, Jeremy Shulman +26 more

Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-21-0455

N/A

0DataRank · unranked

25 citations

Todd M. Pitts, Dana Ungermannova, Christopher G. Nasveschuk, Gan Zhang, Andrew J. Phillips +15 more

WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma

Frontiers in Oncology(2021)10.3389/fonc.2021.642328

N/A

0DataRank · unranked

30 citations

Stacey M. Bagby, Betelehem W. Yacob, Dennis M. Simmons, Morgan MacBeth, Christopher H. Lieu +8 more

Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials

Frontiers in Oncology(2021)10.3389/fonc.2021.640690

N/A

0DataRank · unranked

20 citations

Jodi Kagihara, Jennifer Weiss, Andrew Nicklawsky, Dexiang Gao, Virginia F. Borges +3 more

First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors

Cancers(2023)10.3390/cancers16010091

N/A

0DataRank · unranked

11 citations

Jodi Kagihara, Bradley R. Corr, S. Lindsey Davis, Christopher H. Lieu, Sunnie S. Kim +14 more

Co-regulator activity of Mediator of DNA Damage Checkpoint 1 (MDC1) is associated with DNA repair dysfunction and PARP inhibitor sensitivity in lobular carcinoma of the breast

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.10.29.564555

N/A

0DataRank · unranked

3 citations

Madeleine T. Shackleford, Camryn S. Nesiba, Amanda L. Richer, Zoë Fleischmann, Jordan M. Swartz +11 more

Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

(2023)10.1158/1535-7163.c.6543273.v1

N/A

0DataRank · unranked

0 citations

Todd M. Pitts, Dana Ungermannova, Christopher G. Nasveschuk, Gan Zhang, Andrew J. K. Phillips +15 more

Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

(2023)10.1158/1535-7163.c.6543273

N/A

0DataRank · unranked

0 citations

Todd M. Pitts, Dana Ungermannova, Christopher G. Nasveschuk, Gan Zhang, Andrew J. K. Phillips +15 more

358P Major adverse cardiovascular event outcomes of adjuvant taxane + anthracycline versus taxane-based chemotherapy in older adults with triple-negative breast cancer: A SEER-Medicare study

Annals of Oncology(2023)10.1016/j.annonc.2023.09.537

N/A

0DataRank · unranked

0 citations

Stephanie Lakritz, Anna Schreiber, Ezequiel Molina, Cathy J. Bradley, Laxmi A. Kondapalli +2 more

Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis

Breast Cancer Research(2024)10.1186/s13058-024-01799-5

N/A

0DataRank · unranked

29 citations

Anna Schreiber, Marilyn M. Jackson, Stacey M. Bagby, Adrian T A. Dominguez, Evan D. Dus +6 more

Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer

Clinical Breast Cancer(2025)10.1016/j.clbc.2025.06.004

N/A

0DataRank · unranked

3 citations

Hannah Parris, Long Liu, Stephanie Giangiuli, Dexiang Gao, Jennifer R. Diamond +4 more

RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer

BMC Cancer(2020)10.1186/s12885-020-07500-1

N/A

0DataRank · unranked

30 citations

Julie Lang, Anna Capasso, Deog Joong Kim, Ely Benaim, Young Bok Lee +10 more

Increased accrual of diverse patient populations in oncology phase I clinical trials at the University of Colorado Cancer Center

Frontiers in Oncology(2025)10.3389/fonc.2025.1546500

N/A

0DataRank · unranked

0 citations

Sama L. Kareem, Bradley R. Corr, Christopher H. Lieu, Breelyn A. Wilky, S. Lindsey Davis +9 more